Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Gross Margin (2016 - 2024)

Regenxbio (RGNX) has 11 years of Gross Margin data on record, last reported at 70.22% in Q4 2024.

  • For Q4 2024, Gross Margin rose 2081.0% year-over-year to 70.22%; the TTM value through Dec 2024 reached 59.72%, up 95.0%, while the annual FY2024 figure was 59.72%, 95.0% up from the prior year.
  • Gross Margin reached 70.22% in Q4 2024 per RGNX's latest filing, up from 48.81% in the prior quarter.
  • Across five years, Gross Margin topped out at 94.22% in Q4 2021 and bottomed at 29.26% in Q1 2022.
  • Average Gross Margin over 5 years is 62.32%, with a median of 58.19% recorded in 2022.
  • Peak YoY movement for Gross Margin: crashed -4505bps in 2022, then skyrocketed 4925bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 52.17% in 2020, then skyrocketed by 81bps to 94.22% in 2021, then crashed by -37bps to 59.22% in 2022, then dropped by -17bps to 49.41% in 2023, then surged by 42bps to 70.22% in 2024.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 70.22% in Q4 2024, 48.81% in Q3 2024, and 52.55% in Q2 2024.